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Abstract
Background: Podocalyxin-like protein (PODXL) is a cell surface transmembrane glycoprotein, the expression
of which has been associated with poor prognosis in a range of malignancies. The aim of this study was to
investigate the impact of PODXL expression on survival in esophageal and gastric adenocarcinoma.
Methods: The study cohort consists of a consecutive series of 174 patients with esophageal (including the
gastroesophageal junction) or gastric adenocarcinoma, surgically treated between 2006 and 2010 and not
subjected to neoadjuvant treatment. Immunohistochemical expression of PODXL was assessed in tissue microarrays
with cores from primary tumors, lymph node metastases, intestinal metaplasia and adjacent normal epithelium. Survival
analyses were performed on patients with no distant metastases and no macroscopic residual tumor.
Results: In the majority of cases, expression of PODXL was significantly higher in cancer cells compared to
normal epithelial cells and was significantly associated with lymph node metastases and high grade tumors.
In esophageal adenocarcinoma, Kaplan-Meier analyses revealed that patients with PODXL negative tumors had
a superior time to recurrence (TTR) and overall survival (OS) compared to patients with PODXL positive tumors. In
gastric adenocarcinoma, patients with PODXL negative tumors had a superior TTR and a trend towards an improved
OS. In esophageal and gastric adenocarcinoma combined, the prognostic significance of PODXL expression on TTR
was confirmed in unadjusted Cox regression analysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and remained significant
in the adjusted model (HR = 3.39, 95 % CI 1.01-11.35, p = 0.048). Moreover, the impact of PODXL expression on OS was
also confirmed in unadjusted analysis (HR = 2.52, 95 % CI 1.31-4.85, p = 0.006) and remained significant in the adjusted
model (HR = 2.03, 95 % CI 1.04-3.98, p = 0.039).
Conclusions: In esophageal and gastric adenocarcinoma, PODXL expression is an independent prognostic biomarker
for reduced time to recurrence and poor overall survival. This is the first report on the prognostic role of PODXL
in esophageal adenocarcinoma and validates recent findings in gastric cancer.
Keywords: Esophageal neoplasms, Stomach neoplasms, Adenocarcinoma, Prognosis, PODXL
* Correspondence: david.borg@med.lu.se
Department of Clinical Sciences Lund, Division of Oncology and Pathology,
Lund University, Skåne University Hospital, SE-221 85 Lund, Sweden
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Borg et al. BMC Clinical Pathology  (2016) 16:13 
DOI 10.1186/s12907-016-0034-8
Background
Esophageal and gastric cancers are among the most
common types of cancer worldwide in terms of inci-
dence and mortality [1]. Historically, the majority of
esophageal cancers were squamous cell carcinomas, but
in the last four decades there has been a drastic increase
in the incidence of adenocarcinoma, especially in many
Western countries, where it is now the most common
subtype [2]. Adenocarcinoma in the esophagogastric (EG)
junction is, since the 7th edition of the AJCC/UICC TNM
staging system [3], classified as esophageal cancer. Proposed
risk factors for esophageal and EG junction adenocarcin-
oma are gastroesophageal reflux disease, obesity and de-
creased prevalence of Helicobacter pylori infection [4, 5].
Regarding gastric adenocarcinoma, the incidence has been
declining for several decades [6], possibly due to improved
sanitary conditions and decreased prevalence of Helicobac-
ter pylori infection [7], but globally it is still the 3rd leading
cause of cancer death.
In resectable esophageal and gastric cancer, several
phase III trials [8–13] have shown that the addition of
neoadjuvant and/or adjuvant chemotherapy or chemora-
diotherapy improves survival. However, the prognosis is
still poor, especially in Western populations, with 5-year
survival rates less than 40 %.
Hence, in addition to primary prevention and earlier
detection, the key to improved outcome for patients
with esophageal and gastric cancer is to find more ef-
fective treatments and also to personalize the treatment
based on prognostic and response predictive factors.
Podocalyxin-like protein (PODXL) is a cell surface
transmembrane glycoprotein, belonging to the CD34 fam-
ily, that is encoded on chromosome 7q32-q33. It was first
discovered in renal podocytes as an anti-adhesive protein
[14] and has later been shown to be expressed in vascular
endothelium [15] and to be involved in hematopoiesis [16]
and neural development [17]. PODXL is expressed in a
range of malignancies and overexpression has mostly been
linked to poor prognosis, e.g. in glioblastoma multi-
forme [18], breast cancer [19], bladder cancer [20],
periampullary and pancreatic adenocarcinoma [21, 22]
and colorectal cancer [23–25]. Laitinen et al. [26] re-
cently showed that in surgically treated gastric cancer,
patients with PODXL negative tumors had a signifi-
cantly better cancer-specific 5-year survival than pa-
tients with PODXL positive tumors.
The functional role of PODXL in tumorigenesis is
largely unknown, but it has been demonstrated to pro-
mote cancer cell invasion and migration and to enhance
metastatic potential [27–29]. Other proposed mechanisms
are evasion of natural killer cell-mediated cytotoxicity [30]
and maintaining and regulating the surface expression of
glucose transporters [31]. In osteosarcoma cell lines,
PODXL has been shown to promote chemoresistance to
cisplatin [32], which is particularly interesting since plat-
inum compounds (cisplatin and oxaliplatin) are important
cytotoxic drugs in the treatment of esophageal and gastric
adenocarcinoma.
To our best knowledge, there are no reports on the
prognostic value of PODXL expression in esophageal
adenocarcinoma.
The aim of this study was to explore the expression of
PODXL in both esophageal and gastric adenocarcinoma
and to assess its impact on time to recurrence (TTR)
and overall survival (OS) in a consecutive series of pa-
tients from southern Sweden, treated surgically between
2006 and 2010, prior to the wide implementation of neo-
adjuvant treatment.
Methods
Study design and participants
The study cohort consists of a consecutive series of 174
patients with chemo-/radiotherapy-naive esophageal
(including EG junction) or gastric adenocarcinoma, sub-
jected to surgical resection at the University Hospitals of
Lund and Malmö between January 1, 2006 and Decem-
ber 31, 2010. This cohort has been examined in several
previous biomarker studies [33–37]. Data on survival
and recurrence were updated until December 31, 2014.
Tumor location was based on endoscopy findings. Clas-
sification of tumor stage was done according to the 7th
edition of the UICC/AJCC TNM classification [3]. His-
totype according to Laurén [38] was denoted for all tu-
mors as intestinal, mixed or diffuse growth pattern. This
classification is generally applied on gastric cancer but
can be used also for esophageal and EG junction adeno-
carcinoma. Residual tumor status was classified as: R0 =
no residual tumor (free resection margins according to
pathology report), R1 = possible microscopic residual
tumor (narrow or compromised resection margins ac-
cording to pathology report), R2 =macroscopic residual
tumor (according to surgery report). The vast majority
(98.7 %) of the patients were operated on with a curative
intent but three patients with known distant metastases
(M1-disease) were resected to palliate symptoms from
the primary tumor. In 16 patients, M1-disease was re-
vealed either during surgery or in the resected speci-
mens. No patients received neoadjuvant oncological
therapy and only a minority (7.5 %) of the patients
received adjuvant treatment (chemo-/radiotherapy).
Clinical data, recurrence status and vital status were
obtained retrospectively from medical records. Clinico-
pathological factors and follow-up data are described in
Additional file 1.
Tissue microarrays
Tissue microarrays (TMAs) were constructed using a
semi-automated arraying device (TMArrayer™, Pathology
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Devices, Westminster, MD, USA). From all 174 primary
tumors, duplicate cores (1 mm) from separate donor
blocks were obtained. In 81 cases lymph node metasta-
ses were sampled in duplicate cores (each from a separ-
ate metastasis if more than one). In addition 1–3 cores
from areas with intestinal metaplasia (Barrett’s esopha-
gus or gastric intestinal metaplasia) were sampled in 73
cases. Single core samples from adjacent normal esopha-
geal squamous epithelium (96 cases) and normal gastric
columnar epithelium (131 cases) were also retrieved. All
samples were paired.
Immunohistochemistry
For immunohistochemical analysis of PODXL expres-
sion, 4 μm TMA-sections were automatically pre-treated
using the PT Link system and then stained in an Auto-
stainer Plus (DAKO; Glostrup, Copenhagen, Denmark)
with the rabbit polyclonal anti-PODXL antibody
HPA002110 (Atlas Antibodies AB, Stockholm, Sweden)
diluted 1:250. The same antibody was used by Laitinen
et al. in their study on gastric cancer [26], and the speci-
ficity of the antibody has been validated previously [39].
Staining was assessed simultaneously by two different
observers (KJ and DB) blinded to clinical and outcome
data and scoring discrepancies were discussed to
reach consensus. As in previous studies from our
group [20, 21, 24, 25, 40], assessment of PODXL staining
was registered as negative (0), weak cytoplasmic positivity
in any proportion of cells (1), moderate cytoplasmic posi-
tivity in any proportion of cells (2), distinct membranous
positivity in ≤50 % of cells (3) and distinct membranous
positivity in >50 % of cells (4). For samples with duplicate
cores the highest staining score was used.
Statistical analysis
For description of the cohort and in the analyses of the
association between PODXL expression and clinicopath-
ological factors, chi-square test (Fisher’s exact for 2x2
tables and linear-by-linear association for tables with
more than two rows) was used for categorical variables
and Mann–Whitney U test for continuous variables. The
Mann–Whitney U test was used to assess differences in
PODXL expression between tissue types. In the analyses
of the association between PODXL expression and clini-
copathological factors and in the survival analyses, a
dichotomized variable of negative (staining score 0) vs.
positive (staining score 1–4) PODXL expression in the
primary tumor and/or lymph node metastases was ap-
plied. The cut-off between negative and positive PODXL
expression was the same as used in the study by Laitinen
et al. in gastric cancer [26]. TTR was defined as time
from diagnosis (date of result of the preoperative biopsy)
to the date of biopsy or radiology proven recurrent
disease. OS was defined as time from diagnosis (date of
result of the preoperative biopsy) to the date of death.
TTR and OS were analyzed for resected patients with
M0-disease and no macroscopic residual tumor (R0-1).
Differences in Kaplan-Meier survival curves were com-
puted using log-rank test. Unadjusted and adjusted
hazard ratios (HR) for survival were determined using
Cox proportional-hazards regression. For TTR we ad-
justed for T stage, N stage, R classification, differenti-
ation grade and adjuvant treatment. For OS, the
adjusted model included age, T stage, N stage, R classi-
fication and differentiation grade. All tests were 2-sided
and a p-value <0.05 was considered significant. IBM®
SPSS® Statistics version 22.0.0.1 for Mac was used for
all statistical analyses.
Results
PODXL expression in normal epithelium, intestinal
metaplasia, primary tumors and lymph node metastases
Immunohistochemical expression of PODXL could be
assessed in 50/96 (52 %) samples with normal esopha-
geal squamous epithelium, 79/131 (60 %) samples with
normal gastric columnar epithelium, 51/73 (70 %) sam-
ples with intestinal metaplasia (Barrett’s esophagus or
gastric intestinal metaplasia), 170/174 (98 %) samples
with primary tumors, and 76/81 (94 %) samples with
lymph node metastases. PODXL staining was mainly de-
tected in the cytoplasm, sometimes in a granular pattern,
with or without an accentuation towards the membrane,
and in some cases with a strong membranous compo-
nent. Sample images are shown in Fig. 1. As expected
there was a strong staining in endothelial cells, thus
serving as an internal positive control. The distribution
of immunohistochemical expression of PODXL in the
different tissue types is shown in Fig. 2. Expression of
PODXL was significantly higher in intestinal metaplasia
(Barrett’s esophagus or gastric intestinal metaplasia)
compared to normal epithelium (p < 0.001) and PODXL
expression was significantly higher in primary tumors
and lymph node metastases compared to intestinal
metaplasia (p < 0.001). PODXL expression was similar in
Barrett’s esophagus and gastric intestinal metaplasia (p =
0.671, data not shown). There was no significant differ-
ence in PODXL expression between primary tumors
and lymph node metastases (p = 0.645) and PODXL
expression in primary tumors and/or lymph node me-
tastases did not differ significantly by primary tumor
location (p = 0.314, data not shown).
Associations of PODXL expression with
clinicopathological factors
As shown in Table 1, factors significantly associated with
PODXL expression were N stage and high grade tumors.
Negative PODXL expression was denoted in 14.2 % of
the esophageal cancers and in 21.5 % of the gastric
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Fig. 2 Box plots visualizing the distribution of immunohistochemical expression of PODXL in normal squamous epithelium, normal gastric mucosa,
intestinal metaplasia (Barrett’s esophagus or gastric intestinal metaplasia), primary tumors and lymph node metastases in the entire cohort
Fig. 1 Sample immunohistochemical images of PODXL expression (staining score 0–4), magnification x 20. Top panel, from left: Normal squamous
epithelium (0). Normal columnar epithelium (0). Barrett’s esophagus (1). Middle panel, from left: Primary gastric adenocarcinoma, diffuse subtype
(0). Primary gastric adenocarcinoma, intestinal subtype (1). Primary gastric adenocarcinoma, intestinal subtype (2). Bottom panel, from left: Lymph
node metastasis, intestinal subtype (3). Primary esophageal adenocarcinoma, diffuse subtype (3). Lymph node metastasis, intestinal subtype (4)
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cancers, but the difference between locations was not
statistically significant.
Impact of PODXL expression on prognosis
Survival analyses were performed on patients with M0-
disease and no macroscopic residual tumor (R0-1). In
esophageal adenocarcinoma the Kaplan-Meier analyses
(Fig. 3a, c) revealed that patients with PODXL negative
tumors had a superior TTR (estimated recurrence-free
rate at 5 years 75 % vs. 35 %) and OS (estimated surviv-
ing rate at 5 years 69 % vs. 28 %) compared to patients
with PODXL positive tumors. In gastric adenocarcin-
oma, patients with PODXL negative tumors had a super-
ior TTR (estimated recurrence-free rate at 5 years 88 %
vs. 45 %) and a trend towards an improved OS (esti-
mated surviving rate at 5 years 55 % vs. 40 %) in the
Kaplan-Meier analyses (Fig. 3b, d). In esophageal and
gastric adenocarcinoma combined, as shown in Table 2,
the prognostic significance of PODXL expression on
TTR was confirmed in unadjusted Cox regression ana-
lysis (HR = 5.36, 95 % CI 1.68-17.06, p = 0.005) and
remained significant in the adjusted model (HR = 3.39,
95 % CI 1.01-11.35, p = 0.048). Moreover, the impact of
PODXL expression on OS was also confirmed in un-
adjusted analysis (HR = 2.52, 95 % CI 1.31-4.85, p =
0.006) and remained significant in the adjusted model
(HR = 2.03, 95 % CI 1.04-3.98, p = 0.039).
Similar results were obtained when the survival
analyses were stratified by primary tumor location
(Additional file 2), and when considering PODXL ex-
pression in primary tumors and lymph node metas-
tases separately (Additional file 3).
Discussion
In this study on resected esophageal and gastric adeno-
carcinoma we have shown that PODXL is expressed in
the majority of cases and correlates with poor survival,
but in the subgroup of patients with PODXL negative
cancers the prognosis was excellent. This finding applies
to both esophageal and gastric cancer with regard to
both TTR and OS. To our best knowledge, this is the
first report on the prognostic role of PODXL in esopha-
geal adenocarcinoma. Furthermore, in gastric cancer, we
have validated the recent findings from Laitinen et al.
[26] of a negative prognostic impact of PODXL expres-
sion, even though the proportion of PODXL negative
gastric cancer cases were lower in our study (21.5 %
compared to 42.5 %). The reasons for this discrepancy
are not clear, since we used the same polyclonal anti-
body and the same definition for negative vs. positive
PODXL expression. However, whereas Laitinen et al. only
examined primary tumors, we also included lymph node
metastases in our analyses. This resulted in a non-
significant (p = 0.506) decrease in PODXL negative gastric
Table 1 Associations of PODXL expression with
clinicopathological factors
Entire cohort PODXL neg PODXL pos
n (%) n (%) n (%) p-value
171 (100.0) 29 (17.0) 142 (83.0)
Age
≤70 85 (49.7) 12 (41.4) 73 (51.4) 0.416
>70 86 (50.3) 17 (58.6) 69 (48.6)
Sex
Female 39 (22.8) 9 (31.0) 30 (21.1) 0.330
Male 132 (77.2) 20 (69.0) 112 (78.9)
T stage
T1 18 (10.5) 2 (6.9) 16 (11.3) 0.637
T2 32 (18.7) 6 (20.7) 26 (18.3)
T3 94 (55.0) 16 (55.2) 78 (54.9)
T4 27 (15.8) 5 (17.2) 22 (15.5)
N stage
N0 57 (33.3) 16 (55.2) 41 (28.9) 0.006
N1 29 (17.0) 4 (13.8) 25 (17.6)
N2 41 (24.0) 6 (20.7) 35 (24.6)
N3 44 (25.7) 3 (10.3) 41 (28.9)
M stage
M0 152 (88.9) 25 (86.2) 127 (89.4) 0.535
M1 19 (11.1) 4 (13.8) 15 (10.6)
R classification
R0 117 (68.4) 22 (75.9) 95 (66.9) 0.556
R1 45 (26.3) 5 (17.2) 40 (28.2)
R2 9 (5.3) 2 (6.9) 7 (4.9)
Differentiation grade
Low grade 8 (4.7) 4 (13.8) 4 (2.8) 0.023
Intermediate grade 52 (30.4) 10 (34.5) 42 (29.6)
High grade 111 (64.9) 15 (51.7) 96 (67.6)
Lauren classification
Intestinal 119 (69.6) 23 (79.3) 96 (67.6) 0.335
Mixed 9 (5.3) 0 (0.0) 9 (6.3)




106 (62.0) 15 (51.7) 91 (64.1) 0.217
Stomach 65 (38.0) 14 (48.3) 51 (35.9)
R0 = no residual tumor (free resection margins according to pathology report),
R1 = possible microscopic residual tumor (narrow or compromised resection
margins according to pathology report), R2 =macroscopic residual tumor
(according to surgery report)
N1 =metastasis in 1–2 regional lymph nodes, N2 =metastasis in 3–6 regional
lymph nodes, N3 =metastasis in 7 or more regional lymph nodes
The dichotomized variable for age is based on the mean/median age, as
shown in Additional file 1
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cancer cases from 26.6 to 21.5 %. Another factor
could be observer-dependent, such as setting the cut-
off between negative and weak cytoplasmic staining. In
other reports on PODXL as a prognostic marker in colo-
rectal [23–25, 40], pancreatic and periampullary adenocar-
cinoma [21, 22], using the same polyclonal antibody, the
most evident prognostic cut-off was observed for mem-
branous vs. non-membranous expression, with the former
being an independent factor of poor prognosis. However,
in our study and in the report from Laitinen et al., the opti-
mal prognostic cut-off was negative vs. positive, including
membranous, PODXL expression. Hence, further studies
are warranted to determine optimal cut-offs for prognosti-
cation, which may well differ between different types of
cancer. Of note, previous studies on colorectal [41] and
pancreatic [22] cancer, using a monoclonal anti-PODXL
Fig. 3 Kaplan-Meier plots of time to recurrence and overall survival according to PODXL expression in patients with M0-disease and no macroscopic
residual tumor (R0-1). Time to recurrence in a esophageal cancer and b gastric cancer. Overall survival in c esophageal cancer and d gastric cancer
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Table 2 Hazard ratios for recurrence and death (M0, R0-1)
Time to recurrence Overall survival
Unadjusted Adjusted Unadjusted Adjusted
n (events) HR (95 % CI) p-value HR (95 % CI) p-value n (events) HR (95 % CI) p-value HR (95 % CI) p-value
Age
Continuous 136 (72) 1.00 (0.98–1.02) 0.610 151 (104) 1.04 (1.02–1.06) <0.001 1.05 (1.03–1.07) <0.001
Sex
Female 27 (12) 30 (22)
Male 109 (60) 1.18 (0.63–2.19) 0.610 121 (82) 0.81 (0.50–1.29) 0.370
T stage <0.001 0.043 0.010 0.511
T1 18 (3) 19 (7)
T2 27 (8) 2.14 (0.57–8.06) 0.263 1.53 (0.39–5.96) 0.538 30 (19) 2.09 (0.88–4.97) 0.097 1.53 (0.62–3.78) 0.357
T3 77 (51) 6.92 (2.15–22.29) 0.001 3.72 (1.10–12.64) 0.035 86 (66) 3.27 (1.49–7.15) 0.003 1.79 (0.79–4.08) 0.164
T4 14 (10) 8.52 (2.33–31.16) 0.001 3.52 (0.92–13.56) 0.067 16 (12) 3.71 (1.45–9.48) 0.006 1.98 (0.74–5.31) 0.175
N stage
N0 50 (7) 53 (26)
N1-3 86 (65) 9.89 (4.51–21.72) <0.001 7.78 (3.24–18.71) <0.001 98 (78) 2.56 (1.63–4.00) <0.001 2.79 (1.67–4.66) <0.001
R classification
R0 103 (46) 113 (69)
R1 33 (26) 2.89 (1.76–4.74) <0.001 1.38 (0.79–2.41) 0.253 38 (35) 2.75 (1.80–4.20) <0.001 2.07 (1.29–3.31) 0.003
Differentiation grade
Low/Intermediate grade 49 (18) 56 (31)
High grade 87 (54) 2.22 (1.30–3.79) 0.004 1.93 (1.09–3.42) 0.025 95 (73) 1.73 (1.13–2.63) 0.011 1.40 (0.88–2.20) 0.153
Lauren classification
Intestinal 94 (45) 106 (69)
Diffuse/Mixed 42 (27) 1.57 (0.97–2.53) 0.064 45 (35) 1.35 (0.90–2.03) 0.149
Adjuvant treatment
No 126 (63) 138 (94)
Chemo-/radiotherapy 10 (9) 2.12 (1.05–4.28) 0.036 0.96 (0.45–2.06) 0.924 13 (10) 1.20 (0.62–2.30) 0.589
Location
Esophagus + EG junction 86 (49) 99 (69)
Stomach 50 (23) 0.74 (0.45–1.22) 0.239 52 (35) 0.90 (0.60–1.34) 0.592
PODXL expression
Negative 20 (3) 24 (10)
Positive 113 (67) 5.36 (1.68–17.06) 0.005 3.39 (1.01–11.35) 0.048 124 (92) 2.52 (1.31–4.85) 0.006 2.03 (1.04–3.98) 0.039











antibody, demonstrated a correlation between cytoplasmic
PODXL expression and poor survival.
A limitation of this study is its retrospective design. How-
ever, we have managed to access all the necessary clinical
data, except for recurrence status in some cases, and the
tissue specimens have been thoroughly re-examined. Due
to heterogeneity within tumors there is always a risk of
sampling bias with the TMA-technique. However, as we
used duplicate cores from different donor blocks and, when
available, also included cores from lymph node metastases
when denoting the highest PODXL score for each case, the
risk of overestimating the proportion of PODXL negative
cancers should be reduced.
In current practice, most patients with resectable
esophageal or gastric adenocarcinoma receive neoadju-
vant and/or adjuvant chemotherapy or chemoradiother-
apy, but only a minority (10-15 %) of the patients
actually benefit from the oncological treatment [8–13].
For a biomarker to be really useful in clinical decision
making it should not only be prognostic but also be able
to predict whether a patient will benefit from a treat-
ment or not. Further studies on PODXL in esophageal
and gastric adenocarcinoma are warranted to validate its
role as a prognostic biomarker and to explore whether it
also may be useful as a treatment response predictive
biomarker, as suggested in previous studies on colorectal
[24] and periampullary cancer [21].
Conclusions
In summary, we have shown that PODXL is commonly
expressed in esophageal and gastric adenocarcinoma and
associated with lymph node metastases and high grade
tumors. Furthermore, PODXL is an independent prog-
nostic biomarker for reduced time to recurrence and
poor overall survival, but in the subgroup of patients
with PODXL negative tumors the prognosis appears to
be excellent.
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